Natural product-based combinatorial therapy for ageing-associated diseases and Lifespan extension: A therapeutic mix encompassing Glycyrrhetinic acid, Ginsenoside and 4-Bromoflavone (GGB) increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene, 4/November/2017, 11.51 pm

Natural product therapy for body weight control, energy homeostasis and TIIDM:  Puerarin, isolated from Kudzu/Pueraria Montana, decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 4/November/2017, 11.46 pm
November 4, 2017
Natural product therapy for Non-alcoholic fatty liver disease (NAFLD): Linalool, isolated from Coriander, Palmarosa, Sweet orange, and lavender, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 4/November/2017, 11.58 pm
November 4, 2017
Show all

Introduction: What they say

A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, New South Wales 2052, Australia shows that “A conserved NAD+ binding pocket that regulates protein-protein interactions during aging.” This research paper was published, in the 24 March 2017 issue of the journal “Science” [One of the best research journals in Science with an I.F of 34+], by Prof. David A. Sinclair, Jun Li and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Natural product-based combinatorial therapy for ageing-associated diseases and Lifespan extension: A therapeutic mix encompassing Glycyrrhetinic acid, Ginsenoside and 4-Bromoflavone (GGB) increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene

Price 500


What is known?

Prof. David A. Sinclair’s research team has recently shown that: (a) increased levels of NAD+ (found in non-aged tissues) inhibits the interaction the between DBC1 (deleted in breast cancer 1) and PARP1 [poly(adenosine diphosphate–ribose) polymerase]; and promotes DNA repair; (b) decreased levels of NAD+ (found in aged tissues) promotes the interaction between DBC1 and PARP1 and inhibits DNA repair; (c) aged cells/tissues that are low in NAD+ are radiation-sensitive, cancer-prone and prone to accelerated ageing; and (d) ageing-associated diseases can be reversed by increasing the concentration of NAD+ in ageing tissues, suggesting that ageing-associated diseases, in part, can be reversed by NAD+ supplementation in older animals.


From research findings to therapeutic opportunity:

This study suggests, for the first time, a natural product-based therapy for age-associated diseases.

A therapeutic mix encompassing Glycyrrhetinic acid, Ginsenoside and 4-Bromoflavone (GGB), by increasing the expression of its target gene, it may increase the levels of NAMPT and NMN/NAD+. Thereby, it may: (1) increase plasma NMN levels and tissue NAD+ availability; (2) inhibit the interaction between DBC1 and PARP1; (3) augment PARP1’s DNA repair activity; (4) protect against radiation; (5) protect against cancer; and (6) prevent age-associated gene expression pattern and accelerated ageing.

Thus, pharmacological formulations encompassing Glycyrrhetinic acid, Ginsenoside and 4-Bromoflavone (GGB) or their analogues, either alone or in combination with other drugs,” may be used to suppress age-associated overall physiological decline and improve health/life span.[easy_payment currency=”USD”]


Figure1. A therapeutic mix encompassing Glycyrrhetinic acid, Ginsenoside and 4-Bromoflavone (GGB), by increasing NAD+ levels, may suppress ageing-associated overall physiological decline, ageing-associated diseases and improve health/life span

Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How a therapeutic mix encompassing Glycyrrhetinic acid, Ginsenoside and 4-Bromoflavone (GGB) increases the levels of NMN/NAD to inhibit interaction between DBC1 and PARP1 and to promote DNA repair activity

Amount: $500#

* Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Citation: Boominathan, L., Natural product-based combinatorial therapy for ageing-associated diseases and Lifespan extension: A therapeutic mix encompassing Glycyrrhetinic acid, Ginsenoside and 4-Bromoflavone (GGB) increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene, 4/November/2017, 11.53 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite us, kindly drop us a line

Comments are closed.